Company intelligence / Profile preview

Siena Biotech

Siena, Tuscany, Italyorpha.net ↗

Ownership: Private
Employees: ~21
Development stage: Phase 2

Overview

The company had several programs in development, with the most advanced reaching Phase 2 clinical trials. The company has evolved into the Siena Biotech Hub Foundation, which is now focused on pandemic preparedness.

Therapeutic areas: Rare DiseasesOncologyPsychiatryNeurology
Modalities: Small molecule drugs
Industry: Academic Hospital/University/Research

Drug pipeline

1 asset

6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide

Phase 1

Indications: Huntington's disease

Partnerships

RocheWyeth PharmaceuticalsEuropean Commission (coordinator of three Research Projects)

Beyond the preview

Go deeper on Siena Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Siena Biotech.

Explore the full profile